Alopecia Areata: An Updated Review for 2023

    Cathryn Sibbald
    The updated review on Alopecia Areata (AA) for 2023 provides a comprehensive overview of the condition, affecting up to 2% of the global population, and its treatment options. It highlights the role of immune dysregulation, genetic predisposition, and environmental triggers in AA's pathogenesis. Various treatments are discussed, including essential oils, garlic, glycyrrhizin, and micronutrient supplementation, with varying efficacy. Contact immunotherapy and corticosteroids are widely used, while JAK inhibitors like baricitinib show promise, with FDA approval for severe AA. The review underscores the need for more research to optimize treatment strategies, noting that severity at initial consultation is a key prognostic factor.
    Discuss this study in the Community →

    Research cited in this study

    85 / 85 results

    Related Research

    1 / 1 results